Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1784530
Max Phase: Preclinical
Molecular Formula: C46H69N7O11
Molecular Weight: 896.10
Molecule Type: Small molecule
Associated Items:
ID: ALA1784530
Max Phase: Preclinical
Molecular Formula: C46H69N7O11
Molecular Weight: 896.10
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCC(=O)N(C)[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)Cc2cc(N)c(O)c(c2)-c2cc1ccc2O
Standard InChI: InChI=1S/C46H69N7O11/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-38(56)52(4)36(27-54)44(61)49-28(2)42(59)48-26-39(57)53(5)40-31-20-21-37(55)32(25-31)33-22-30(23-34(47)41(33)58)24-35(46(63)64)51-43(60)29(3)50-45(40)62/h20-23,25,28-29,35-36,40,54-55,58H,6-19,24,26-27,47H2,1-5H3,(H,48,59)(H,49,61)(H,50,62)(H,51,60)(H,63,64)/t28-,29+,35+,36-,40+/m1/s1
Standard InChI Key: BKPBVSGPCZGJRY-OBNNQUODSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 896.10 | Molecular Weight (Monoisotopic): 895.5055 | AlogP: 3.40 | #Rotatable Bonds: 23 |
Polar Surface Area: 281.03 | Molecular Species: ACID | HBA: 11 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.43 | CX Basic pKa: 4.17 | CX LogP: 2.18 | CX LogD: -0.20 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.04 | Np Likeness Score: 0.54 |
1. Roberts TC, Smith PA, Romesberg FE.. (2011) Synthesis and biological characterization of arylomycin B antibiotics., 74 (5): [PMID:21545107] [10.1021/np200163g] |
Source(1):